Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antares Pharma has reported total revenue of $3.57m for the first quarter ended 31 March 2011, compared to $3.36m for the same period in 2010.
Subscribe to our email newsletter
The company has reported a net loss of $1.38m, or $0.02 loss per diluted share, compared to net loss of $1.61m or $0.02 loss per diluted share, for the same period last year.
Antares Pharma‘s operating loss was $1.41m, as compared to $1.59m for the same period prior year.
Total gross profit increased in the first quarter of 2011 to $2.1m compared to $2m in 2010, primarily due to the increase in royalties.
Antares Pharma president and CEO Paul Wotton said in addition to a solid operational performance, the first quarter brought a number of important events including the FDA acceptance and granting of a filing fee waiver for their NDA filing for Anturol for OAB.
"We are also excited by the continued development of the novel Vibex MTX product," Wotton said.